Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of IFM-2427 in healthy volunteers
NL-OMON49211Phase 1Completed
- Sponsor
- IFM Therapeutics
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DFV890 in Crohn's disease and Inflammatory Disorders (7 arms), sponsored by IFM Therapeutics. Primary endpoints: Safety and tolerability, Single-dose plasma pharmacokinetics and 3 more. Started Feb 2019; status: completed.
02
Drugs
DFV890
03
Conditions
Crohn's diseaseInflammatory Disorders
Beyond the preview
Go deeper on NL-OMON49211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49211.